BRPI1016109A2 - "composto, composição farmacêutica, e, processo para preparar um composto" - Google Patents
"composto, composição farmacêutica, e, processo para preparar um composto"Info
- Publication number
- BRPI1016109A2 BRPI1016109A2 BRPI1016109A BRPI1016109A BRPI1016109A2 BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2 BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21853909P | 2009-06-19 | 2009-06-19 | |
| PCT/GB2010/051003 WO2010146395A1 (en) | 2009-06-19 | 2010-06-17 | Pyrazine carboxamides as inhibitors of dgat1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016109A2 true BRPI1016109A2 (pt) | 2016-05-17 |
Family
ID=42357808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016109A BRPI1016109A2 (pt) | 2009-06-19 | 2010-06-17 | "composto, composição farmacêutica, e, processo para preparar um composto" |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8188092B2 (pt) |
| EP (1) | EP2443096A1 (pt) |
| JP (1) | JP2012530122A (pt) |
| KR (1) | KR20120037939A (pt) |
| CN (1) | CN102498103A (pt) |
| AR (1) | AR077140A1 (pt) |
| AU (1) | AU2010261499A1 (pt) |
| BR (1) | BRPI1016109A2 (pt) |
| CA (1) | CA2764013A1 (pt) |
| MX (1) | MX2011014018A (pt) |
| RU (1) | RU2011152517A (pt) |
| TW (1) | TW201103895A (pt) |
| UY (1) | UY32716A (pt) |
| WO (1) | WO2010146395A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539818A (ja) * | 2006-06-08 | 2009-11-19 | アストラゼネカ アクチボラグ | ベンゾイミダゾールおよび糖尿病の処置のためのその使用 |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| EP2684879A1 (en) | 2012-07-09 | 2014-01-15 | Basf Se | Substituted mesoionic compounds for combating animal pests |
| JP6099753B2 (ja) | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| EP3495359A1 (en) * | 2013-02-04 | 2019-06-12 | Janssen Pharmaceutica NV | Flap modulators |
| TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
| CN103467392B (zh) * | 2013-10-09 | 2016-08-17 | 重庆工商大学 | 一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途 |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3245989A (en) * | 1962-12-15 | 1966-04-12 | Acraf | 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles |
| US4983731A (en) * | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
| US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| US20030167483A1 (en) * | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US6608185B1 (en) * | 1999-03-25 | 2003-08-19 | Kitasato Institute | Substances KF-1040T4A,KF-1040T4B, KF-1040T5A, and KF-1040T5B, and process for producing same |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| GB0021670D0 (en) * | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2369967A1 (en) * | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
| DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BR0212158A (pt) * | 2001-08-31 | 2004-07-13 | Aventis Pharma Gmbh | Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar |
| WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| FR2840301B1 (fr) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| AU2003242229A1 (en) * | 2002-06-06 | 2003-12-22 | Kansai Technology Licensing Organization Co., Ltd. | Method for producing polycrystalline silicon substrate for solar cell |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
| AU2003249937A1 (en) | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
| WO2004017920A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| EP1551813A4 (en) | 2002-10-10 | 2007-07-11 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| EP1562956A4 (en) | 2002-11-22 | 2007-10-10 | Japan Tobacco Inc | HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN |
| ES2387803T3 (es) | 2003-01-08 | 2012-10-02 | Novartis Vaccines And Diagnostics, Inc. | Agentes antibacterianos |
| JP4847314B2 (ja) | 2003-04-07 | 2011-12-28 | コーティカル・ピーティーワイ・リミテッド | 炎症性疾患を治療するための新規な方法 |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| US20050143464A1 (en) | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
| EP2264030A1 (en) | 2003-10-17 | 2010-12-22 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| JP4820299B2 (ja) | 2003-11-11 | 2011-11-24 | ザ スキニー ドリンク カンパニー | 肥満、心臓血管疾患及び冠状動脈疾患の予防及び治療のための組成物 |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | S1p受容体結合能を有する化合物およびその用途 |
| CA2572874A1 (en) * | 2004-07-02 | 2006-01-12 | Sankyo Company Limited | Urea derivative |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| AU2005295453A1 (en) | 2004-10-15 | 2006-04-27 | Bayer Healthcare Llc | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
| BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
| WO2006082952A1 (ja) | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
| CN101115711A (zh) | 2005-02-07 | 2008-01-30 | 霍夫曼-拉罗奇有限公司 | 二酰基甘油酰基转移酶(dgat)的抑制剂 |
| MX2007013049A (es) | 2005-04-19 | 2008-01-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad. |
| JP2008540485A (ja) | 2005-05-10 | 2008-11-20 | エフ.ホフマン−ラ ロシュ アーゲー | ジアシルグリセロールアシルトランスフェラーゼ阻害剤 |
| CA2610188A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| CA2617055A1 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
| JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
| BRPI0619052A2 (pt) | 2005-11-28 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso |
| JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
| AR058562A1 (es) * | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
| WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
| PT2402319T (pt) * | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| US8088776B2 (en) | 2006-04-21 | 2012-01-03 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US20080015227A1 (en) | 2006-05-19 | 2008-01-17 | Kym Philip R | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
| AU2007266796B2 (en) * | 2006-05-30 | 2011-02-10 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
| EP2035397A1 (en) * | 2006-06-06 | 2009-03-18 | Astra Zeneca AB | Chemical compounds |
| JP2009539818A (ja) | 2006-06-08 | 2009-11-19 | アストラゼネカ アクチボラグ | ベンゾイミダゾールおよび糖尿病の処置のためのその使用 |
| GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| US7569590B2 (en) * | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
| KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
| EP2074096B1 (en) | 2006-10-04 | 2012-06-27 | F. Hoffmann-La Roche AG | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| PE20080888A1 (es) | 2006-10-18 | 2008-08-26 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1) |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| NZ577112A (en) | 2006-11-29 | 2012-03-30 | Abbott Lab | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme compirising substituted bicyclic pyrimidines |
| JP2010512410A (ja) | 2006-12-11 | 2010-04-22 | ノバルティス アーゲー | 心筋虚血を予防または処置するための方法 |
| BRPI0810719A8 (pt) * | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
| US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP2010536839A (ja) | 2007-08-17 | 2010-12-02 | アストラゼネカ アクチボラグ | 化合物979 |
| AR069802A1 (es) * | 2007-12-20 | 2010-02-17 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores de dgat1 190 |
| JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
| TW201024271A (en) * | 2008-12-19 | 2010-07-01 | Astrazeneca Ab | Chemical compounds 553 |
-
2010
- 2010-06-17 MX MX2011014018A patent/MX2011014018A/es not_active Application Discontinuation
- 2010-06-17 TW TW099119725A patent/TW201103895A/zh unknown
- 2010-06-17 WO PCT/GB2010/051003 patent/WO2010146395A1/en not_active Ceased
- 2010-06-17 RU RU2011152517/04A patent/RU2011152517A/ru unknown
- 2010-06-17 CN CN201080036012XA patent/CN102498103A/zh active Pending
- 2010-06-17 UY UY0001032716A patent/UY32716A/es unknown
- 2010-06-17 KR KR1020127001363A patent/KR20120037939A/ko not_active Withdrawn
- 2010-06-17 EP EP10725494A patent/EP2443096A1/en not_active Withdrawn
- 2010-06-17 AU AU2010261499A patent/AU2010261499A1/en not_active Abandoned
- 2010-06-17 JP JP2012515565A patent/JP2012530122A/ja active Pending
- 2010-06-17 BR BRPI1016109A patent/BRPI1016109A2/pt not_active Application Discontinuation
- 2010-06-17 CA CA2764013A patent/CA2764013A1/en not_active Abandoned
- 2010-06-18 US US12/818,187 patent/US8188092B2/en not_active Expired - Fee Related
- 2010-06-18 AR ARP100102161A patent/AR077140A1/es unknown
-
2012
- 2012-04-25 US US13/455,275 patent/US20120289520A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2764013A1 (en) | 2010-12-23 |
| AU2010261499A1 (en) | 2012-01-12 |
| KR20120037939A (ko) | 2012-04-20 |
| TW201103895A (en) | 2011-02-01 |
| EP2443096A1 (en) | 2012-04-25 |
| AR077140A1 (es) | 2011-08-03 |
| US20100324068A1 (en) | 2010-12-23 |
| RU2011152517A (ru) | 2013-07-27 |
| US8188092B2 (en) | 2012-05-29 |
| WO2010146395A1 (en) | 2010-12-23 |
| JP2012530122A (ja) | 2012-11-29 |
| US20120289520A1 (en) | 2012-11-15 |
| UY32716A (es) | 2011-01-31 |
| MX2011014018A (es) | 2012-02-22 |
| CN102498103A (zh) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
| BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
| BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
| BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
| BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
| BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
| BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
| BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI1010128A2 (pt) | "processo para a fabricação do 2,3,3,3 - tetrafluropropeno" | |
| BRPI1011888A2 (pt) | processo para preparar um composto, e, composição. | |
| BRPI0905847A2 (pt) | "composição farmacêutica injetável e processo para preparar a composição" | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
| BRPI0815784A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
| BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
| BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| BRPI0815971A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
| BRPI0813772A2 (pt) | Composto, processo para a preparação de um composto, e, conjugado | |
| BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica | |
| BRPI1014436A2 (pt) | composto, processo de preparação de um composto, intermediário, composições farmacêuticas, e, utilização de um composto. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |